Lyell Immunopharma (LYEL) Leases (2020 - 2025)
Historic Leases for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to $19.9 million.
- Lyell Immunopharma's Leases fell 4568.76% to $19.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.9 million, marking a year-over-year decrease of 4568.76%. This contributed to the annual value of $24.7 million for FY2024, which is 3762.7% down from last year.
- According to the latest figures from Q3 2025, Lyell Immunopharma's Leases is $19.9 million, which was down 4568.76% from $21.0 million recorded in Q2 2025.
- Over the past 5 years, Lyell Immunopharma's Leases peaked at $48.4 million during Q2 2021, and registered a low of $19.9 million during Q3 2025.
- For the 5-year period, Lyell Immunopharma's Leases averaged around $38.1 million, with its median value being $41.1 million (2023).
- In the last 5 years, Lyell Immunopharma's Leases tumbled by 99.77% in 2021 and then plummeted by 4568.76% in 2025.
- Lyell Immunopharma's Leases (Quarter) stood at $46.5 million in 2021, then fell by 7.09% to $43.2 million in 2022, then fell by 8.28% to $39.7 million in 2023, then tumbled by 37.63% to $24.7 million in 2024, then decreased by 19.51% to $19.9 million in 2025.
- Its Leases stands at $19.9 million for Q3 2025, versus $21.0 million for Q2 2025 and $23.6 million for Q1 2025.